Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, has appointed Amy Pott as the new head of Sobi North America. She takes over effective today, replacing Rami Levin who is leaving Sobi.
“Sobi North America is entering a new phase in line with Sobi’s growth strategy, with the workforce growing more than fourfold in just more than a year. The launch of Gamifant [emapalumab] and the integration of Synagis are key to the company’s future and I am delighted to welcome Amy to Sobi for her to take on this challenge,” says Guido Oelkers, chief executive.
Ms Pott was most recently group vice president and US franchise head for Internal Medicine & Oncology at Shire, which has recently been acquired by Japan’s Takeda. She was also group VP for US Commercial Operations at Shire and VP of strategy, planning and analytics at Baxalta, all roles based in Boston. Prior to her roles in the USA, Ms Pott spent 10 years at Baxter, where she held UK and international roles working with both rare diseases and medical devices. During her time in the UK she built up Baxter’s UK & Ireland market access team.
Ms Pott has a strong background in private and public healthcare, having worked as an Associate for APCO Worldwide in London, Sacramento and San Francisco supporting a wide range of public sector companies. Previous to her roles at Baxter and Shire, Pott held positions at the National Institute for Health and Clinical Excellence (NICE) and the NHS Confederation. Amy Pott will be part of the Sobi executive committee.
Source: The Pharma Letter
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
